Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 3:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 143 matching trials from the live ClinicalTrials.gov search.
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Calcium-Rich Food Versus Calcium Carbonate for Bone Health

NCT07763509
Conditions
Osteopenia, Osteoporosis, Bone Health in Perimenopausal Women, Menopause Related Conditions, Fracture Healing
Interventions
500 mg calcium from milk-derived minerals, Calcium Carbonate 500 MG
Other · Dietary Supplement
Lead sponsor
Cornell University
Other
Eligibility
40 Years to 90 Years · Female only
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Primary Hyperparathyroidism, Osteoporosis, Postmenopausal
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
50 Years to 100 Years · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Osteopenia, Osteoporosis
Interventions
BPS804 20mg/Kg, Placebo to 20mg/Kg BPS804
Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
45 Years to 85 Years · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Anaheim, California • Miami, Florida • Berlin, New Jersey + 1 more
Conditions
Postmenopausal Osteoporosis
Interventions
Strength/Weight Training & Drug/Supplement, Drug/Supplement only
Other · Combination Product
Lead sponsor
University of Nebraska
Other
Eligibility
35 Years to 75 Years · Female only
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
4
States / cities
Kearney, Nebraska • Lincoln, Nebraska • Omaha, Nebraska + 1 more
Completed Not applicable Interventional Accepts healthy volunteers

Hesperidin and Bone Health in Postmenopausal Women

NCT01881204
Conditions
Osteoporosis, Postmenopausal
Interventions
Hesperidin and Calcilock, Hesperidin, Control
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
West Lafayette, Indiana
Conditions
Osteoporosis
Interventions
zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years to 79 Years · Female only
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
12
States / cities
Santa Rosa, California • Lakewood, Colorado • Gainsville, Florida + 9 more
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

NCT04467983
Conditions
Osteoporosis, Postmenopausal
Interventions
Denosumab Injection, Abaloparatide
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
45 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption

NCT01750086
Conditions
Postmenopausal Osteoporosis
Interventions
Teriparatide 40-mcg subcutaneous injection, Denosumab Injection, Alendronate Oral Tablet
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 3 Interventional Accepts healthy volunteers

Vitamin K and Bone Turnover in Postmenopausal Women

NCT00062595
Conditions
Osteoporosis
Interventions
phylloquinone (K1), menatetranone (MK4)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Female only
Enrollment
375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2004
U.S. locations
1
States / cities
Madison, Wisconsin
Completed Phase 2 Interventional Accepts healthy volunteers

Atenolol for the Prevention of Osteoporosis (APO)

NCT04905277
Conditions
Healthy
Interventions
Atenolol 50 MG, Placebo
Drug
Lead sponsor
Sundeep Khosla, M.D.
Other
Eligibility
50 Years to 75 Years · Female only
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
3
States / cities
Scarborough, Maine • Rochester, Minnesota • New York, New York
Conditions
Osteoporosis
Interventions
Ronacaleret, Teriparatide, Alendronate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years · Female only
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Oakland, California • Palm Desert, California • Walnut Creek, California + 6 more
Conditions
Postmenopausal Osteoporosis
Interventions
Alendronate, Ibandronate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Female only
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
54
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tempe, Arizona + 47 more
Conditions
Post-Menopausal Osteoporosis
Interventions
ibandronate [Bonviva/Boniva]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Female only
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
5
States / cities
Loma Linda, California • Lakewood, Colorado • Omaha, Nebraska + 2 more
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Anabolic Therapy in Postmenopausal Osteoporosis

NCT05010590
Conditions
Postmenopausal Osteoporosis
Interventions
Romosozumab, Denosumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Completed No phase listed Observational Accepts healthy volunteers

Fosamax Bone Loss Study: Alendronate to Prevent Bone Loss

NCT00221312
Conditions
Perimenopausal Bone Loss
Interventions
Fosamax
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 54 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2007
U.S. locations
1
States / cities
San Francisco, California
Completed Phase 3 Interventional Results available

A Study of Monthly Risedronate for Osteoporosis

NCT00247273
Conditions
Postmenopausal Osteoporosis
Interventions
risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
50 Years and older · Female only
Enrollment
1,294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
7
States / cities
Lakewood, Colorado • Gainesville, Georgia • Bethesda, Maryland + 4 more
Conditions
Post Menopausal Osteoporosis
Interventions
Ibandronate [Bonviva/Boniva], Calcium, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
1,609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
20
States / cities
Irvine, California • Loma Linda, California • Los Angeles, California + 17 more
Conditions
Postmenopausal Women With Osteoporosis
Interventions
Romosozumab, Alendronate, Placebo to Romosozumab, Placebo to Alendronate
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 90 Years · Female only
Enrollment
4,093 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
32
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 29 more
Conditions
Osteoporosis, Osteopenia
Interventions
Nitroglycerin ointment, Calcium supplement with vitamin D
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
40 Years to 65 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2007
U.S. locations
1
States / cities
New Brunswick, New Jersey
Conditions
Postmenopausal Osteoporosis
Interventions
RGB-14-P, Prolia®
Drug
Lead sponsor
Gedeon Richter Plc.
Industry
Eligibility
60 Years to 90 Years · Female only
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Miami, Florida • Miami Lakes, Florida • Decatur, Georgia + 1 more
Conditions
Postmenopausal Osteoporosis, Osteoporosis
Interventions
synthetic hPTH 1-34
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
46 Years to 85 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Osteoporosis, Postmenopausal
Interventions
LY333334, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
Female only
Enrollment
251 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Daytona Beach, Florida • Honolulu, Hawaii
Conditions
Osteoporosis, Post-Menopausal
Interventions
Raloxifene, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
2
States / cities
Indianapolis, Indiana • Omaha, Nebraska
Conditions
Osteoporosis, Postmenopausal
Interventions
TVB-009, Prolia®
Combination Product
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
60 Years to 90 Years · Female only
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
20
States / cities
Phoenix, Arizona • Tucson, Arizona • San Diego, California + 17 more